- Home
- CPOP vs HURA Comparison
CPOP vs HURA Comparison
Compare CPOP & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPOP | HURA |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 35.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CPOP | HURA |
|---|---|---|
| Price | $0.36 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 93.7K | ★ 2.9M |
| Earning Date | 11-17-2025 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,632,769.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 127.16 | N/A |
| 52 Week Low | $0.33 | $0.41 |
| 52 Week High | $2.61 | $4.77 |
Technical Indicators
Market Signals| Indicator | CPOP | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 72.34 |
| Support Level | $0.33 | $0.42 |
| Resistance Level | $0.46 | $0.75 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 29.75 | 77.73 |
Price Performance
Historical ComparisonAbout CPOP Pop Culture Group Co. Ltd
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.